

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 57622

Manuscript Type: MINIREVIEWS

Contemporary treatment approaches for metastatic colorectal cancer driven by *BRAF* V600 mutations

Kanat O *et al.* Treatment of BRAF-mutant metastatic colorectal cancer

Ozkan Kanat, Hulya Ertas, Burcu Caner

Ozkan Kanat, Department of Medical Oncology, Acibadem Bursa Hospital, Bursa 16059, Turkey

Match Overview

1	Internet 91 words crawled on 01-Jul-2020 www.mdpi.com	2%
2	Crossref 62 words Carolina Bernabe-Ramirez, Rajvi Patel, Jaspreet Chahal, ... Muhammad Wasif Saif. "Treatment options in BRAF-mutan	1%
3	Internet 27 words crawled on 11-Jun-2019 cancerdiscovery.aacrjournals.org	1%
4	Crossref 24 words Matthew Burge, Timothy Price, Christos S. Karapetis. "First -line therapy for metastatic colorectal cancer: Current per ...	1%
5	Internet 18 words crawled on 26-Mar-2018 www.dovepress.com	<1%
6	Crossref 18 words Gábor Lakatos, Claus-Henning Köhne, György Bodoky. "C	<1%

ALL

IMAGES

VIDEOS

29,800 Results

Any time ▼

BRAF Mutation in Colorectal Cancer: An Update

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562608>

Sep 06, 2015 · Similarly, another study showed the generation of a genetically engineered mouse model for **BRAF V600E colorectal** and its subsequent **treatment** with **combinatorial anti-BRAF** and dual anti-PI3K/mTOR. 36 Tumor growth was found to be synergistically affected by the combination of both drugs. Altogether, the material reviewed so far suggests that the **combinatorial approaches of multiple protein inhibitors in cancer therapy** ...

Cited by: 85**Author:** David Barras**Publish Year:** 2015

Impact of BRAF Mutations on Metastatic Colorectal Cancer

<https://www.onclive.com/.../impact-of-braf-mutations-on-metastatic-colorectal-cancer> ▼

Mar 03, 2020 · Scott Kopetz, **MD**, PhD: The patients with a **BRAF V600E mutation** represent a very distinct subgroup of **patients with colorectal cancer**. They have a very different molecular profile, meaning other ...

Molecular targeted therapy of BRAF-mutant colorectal cancer

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582307>

Jun 18, 2019 · **Van CE, Kohne CH, Lang I, et al.** Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to **tumor KRAS** and BRAF mutation status. J Clin Oncol 2011; 29: 2011–2019. [Google Scholar]

Cited by: 4**Author:** Michel Ducreux, Ali Chamseddine, Pierr...**Publish Year:** 2019

Targeting BRAF in metastatic colorectal cancer: Maximizing ...

<https://www.sciencedirect.com/science/article/pii/S0305737217301299>

A recent report showed that the combination of a **BRAF inhibitor** and a MEK inhibitor in the

Contemporary treatment approaches for metastatic colorectal cancer



ALL

IMAGES

VIDEOS

28,600 Results

Any time ▾

Exploring the best treatment options for BRAF-mutant ...

<https://www.nature.com/articles/s41416-019-0526-2>

Jul 29, 2019 · The **BRAF** V600E mutation is a well-accepted poor prognostic factor in patients with **metastatic colorectal cancer** (mCRC), as it confers Ras-independent stimulation of ...

Cited by: 4

Author: Julien Taieb, Alexandra Lapeyre-Prost, ...

Publish Year: 2019

Applying Precision to the Management of BRAF-Mutant ...

<https://link.springer.com/article/10.1007/s11523-020-00747-5> ▾

A deeper understanding of predominant resistance mechanisms in **BRAFV600E mCRC** after exposure to **BRAF inhibition** has resulted in innovative **combinatorial approaches** targeting the **mitogen-activated protein kinase** (MAPK) pathway, revitalizing the **treatment** portfolio for these patients.

New therapeutic strategies for BRAF mutant colorectal cancers

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671849>

Jan 16, 2015 · **BRAF V600 mutations** are also found in ~50% of melanomas. **BRAF inhibitors**, such as vemurafenib and dabrafenib, have produced dramatic response rates of 50-80% in **BRAF mutant melanoma**, revolutionizing the **treatment** of these **cancers** (14-17). Both vemurafenib and dabrafenib are FDA-approved for the **treatment of BRAF mutant melanoma**.

Cited by: 15

Author: Ryan B. Corcoran

Publish Year: 2015

BRAF Mutated Colorectal Cancer: New Treatment Approaches

<https://www.mdpi.com/2072-6694/12/6/1571/htm> ▾

Colon cancer is one of the most frequently diagnosed malignancies in adults, considering both its incidence and prevalence. Anatomically, the right **colon** is considered as being from the cecum to the splenic flexure, and the left **colon** is from the splenic flexure to the rectum. Sidedness is a surrogate



58,100 Results

Any time ▾

[Exploring the best treatment options for BRAF-mutant ...](#)

<https://www.nature.com/articles/s41416-019-0526-2>

Jul 29, 2019 - The **BRAF** V600E mutation is a well-accepted poor prognostic factor in patients with **metastatic colorectal cancer** (mCRC), as it confers Ras-independent stimulation of ...

Cited by: 4**Author:** Julien Taieb, Alexandra Lapeyre-Prost, Pi...**Publish Year:** 2019

[Evolving Strategies for the Management of BRAF-Mutant ...](#)

<https://www.cancernetwork.com/view/evolving...> ▾

Jun 19, 2019 - Detection of the **BRAF** V600E mutation has important genetic, prognostic, and therapeutic implications for patients with **metastatic colorectal cancer** (mCRC), as it aids in the identification of a subgroup of patients who derive little benefit from standard treatments and have an extremely poor prognosis. Secondary analyses of **BRAF** V600E-mutated subsets from multiple randomized clinical ...

[New therapeutic strategies for BRAF mutant colorectal cancers](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671849>

Jan 16, 2015 - **BRAF V600 mutations** are also found in ~50% of melanomas. **BRAF inhibitors**, such as vemurafenib and dabrafenib, have produced dramatic response rates of 50-80% in **BRAF mutant melanoma**, revolutionizing the **treatment** of these **cancers** (14-17). Both vemurafenib and dabrafenib are FDA-approved for the **treatment of BRAF mutant melanoma**.

Cited by: 16**Author:** Ryan B. Corcoran**Publish Year:** 2015

[BRAF Mutated Colorectal Cancer: New Treatment Approaches](#)

<https://www.mdpi.com/2072-6694/12/6/1571/htm> ▾

Colon cancer is one of the most frequently diagnosed malignancies in adults, considering both its incidence and prevalence. Anatomically, the right **colon** is considered as being from the cecum to the splenic flexure, and the left **colon** is from the splenic flexure to the rectum. Sidedness is a surrogate of a wide spectrum of **colorectal cancer** (CRC) biology features (embryology, microbiome ...

Author: Javier Molina-Cerrillo, María San Rom...**Publish Year:** 2020

[Impact of BRAF Mutations on Metastatic Colorectal Cancer](#)